We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+2.29%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$1.1B
AUM Growth
+$93.7M
Cap. Flow
+$96.1M
Cap. Flow %
8.76%
Top 10 Hldgs %
40.44%
Holding
102
New
24
Increased
37
Reduced
19
Closed
19

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$22.3M
2
ABT icon
Abbott
ABT
+$15.9M
3
NTRA icon
Natera
NTRA
+$12.9M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$12.8M
5
MMSI icon
Merit Medical Systems
MMSI
+$12.7M

Top Sells

Rank Stock Value
1
ADMA icon
ADMA Biologics
ADMA
+$23.2M
2
MDT icon
Medtronic
MDT
+$20.5M
3
MRK icon
Merck
MRK
+$19.8M
4
CNC icon
Centene
CNC
+$18.9M
5
UTHR icon
United Therapeutics
UTHR
+$13.9M

Sector Composition

Rank Sector Weight
1 Healthcare 85.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLLN
51
BillionToOne Inc
BLLN
$5.9B
$6.95M 0.63%
88,069
+522
+0.6% +$42.7K
CAH icon
52
Cardinal Health
CAH
$53B
$6.75M 0.62%
31,941
-30,400
-49% -$6.55M
ICLR icon
53
Icon
ICLR
$12.9B
$6.36M 0.58%
57,500
-57,836
-50% -$7.9M
ALHC icon
54
Alignment Healthcare
ALHC
$4.35B
$6.34M 0.58%
+359,826
New +$7.23M
HCA icon
55
HCA Healthcare
HCA
$82.8B
$6.32M 0.58%
13,351
-514
-4% -$259K
GPCR icon
56
Structure Therapeutics
GPCR
$3.54B
$6.09M 0.56%
126,383
+58,135
+85% +$3.98M
ROIV icon
57
Roivant Sciences
ROIV
$25B
$5.75M 0.52%
+207,446
New +$5.33M
OSCR icon
58
Oscar Health
OSCR
$9.08B
$5.73M 0.52%
499,837
– –
SNDX icon
59
Syndax Pharmaceuticals
SNDX
$1.96B
$5.72M 0.52%
245,021
+2,054
+0.8% +$44.6K
TARS icon
60
Tarsus Pharmaceuticals
TARS
$2.52B
$5.63M 0.51%
80,226
+52,888
+193% +$3.7M
PSNL icon
61
Personalis
PSNL
$1.37B
$5.54M 0.51%
870,097
+64,280
+8% +$543K
ASND icon
62
CALL
Ascendis Pharma A/S
ASND
$16.6B
$5.12M 0.47%
+22,400
New +$5.02M
KOD icon
63
Kodiak Sciences
KOD
$2.64B
$4.37M 0.4%
+114,719
New +$2.96M
ARWR icon
64
Arrowhead Research
ARWR
$12.8B
$4.03M 0.37%
+64,279
New +$4.07M
EPRX
65
Eupraxia Pharmaceuticals
EPRX
$426M
$3.92M 0.36%
+540,871
New +$4.35M
DFTX
66
Definium Therapeutics
DFTX
$5.86B
$3.88M 0.35%
+205,317
New +$3.48M
MLYS icon
67
Mineralys Therapeutics
MLYS
$2.38B
$3.87M 0.35%
142,677
+95,040
+200% +$2.79M
MDLN
68
Medline Inc
MDLN
$32.2B
$3.86M 0.35%
86,777
+1,777
+2% +$78.5K
CAPR icon
69
Capricor Therapeutics
CAPR
$1.12B
$3.76M 0.34%
+123,831
New +$3.3M
ILMN icon
70
Illumina
ILMN
$29.2B
$3.56M 0.32%
+28,869
New +$3.79M
ARGX icon
71
argenx
ARGX
$54.1B
$3.31M 0.3%
4,535
+333
+8% +$261K
CGEM icon
72
Cullinan Oncology
CGEM
$1.09B
$3.23M 0.29%
227,406
+403
+0.2% +$5.18K
ABVX
73
Abivax
ABVX
$11.4B
$2.97M 0.27%
26,664
-5,214
-16% -$617K
OM icon
74
Outset Medical
OM
$77.5M
$2.28M 0.21%
594,630
+63,834
+12% +$262K
HCA icon
75
PUT
HCA Healthcare
HCA
$82.8B
$2.18M 0.2%
+4,600
New +$2.32M
1 2
3
4 5

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
CPRC
Consolidated Portfolio Review Corp Woodbury, New York $1.1B AUM 8.96% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return

PFM Health Sciences's Q1 2026 Portfolio in Review

As of Q1 2026, PFM Health Sciences held 102 positions worth $1.1B, up 9.3% from $1B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

PFM Health Sciences deployed $96.1M of net new capital in Q1 2026, opening 24 new positions and adding to 37 existing holdings. Its largest new stake was Abbott: 140,432 shares worth $14.4M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 97% a quarter earlier.

On the sell side, the largest reduction was Centene, an estimated $18.9M trimmed.

  • PFM Health Sciences's largest Q1 2026 buy was Abbott: 140,432 shares worth $14.4M.
  • PFM Health Sciences added most to Jazz Pharmaceuticals in Q1 2026, an estimated $22.3M increase.
  • PFM Health Sciences's biggest Q1 2026 reduction was Centene, cutting an estimated $18.9M.
  • PFM Health Sciences fully exited ADMA Biologics in Q1 2026, selling an estimated $23.2M.
  • PFM Health Sciences's ten largest holdings make up 40% of its $1.1B portfolio in Q1 2026.
  • PFM Health Sciences opened 24 new positions and closed 19 in Q1 2026.
  • PFM Health Sciences's portfolio value rose 9.3% quarter-over-quarter to $1.1B.

Based on PFM Health Sciences's 13F filing for Q1 2026, filed 15 May 2026.